Program
Click here to download the detailed program.
Time | Session Information - Wednesday April 24, 2019 | |
---|---|---|
12:00 - 13:00 | Registration and Lunch | |
The Conceptual Challenges | ||
13:00 - 13:20 | The Challenge of PD as many Diseases - Clinical, Genetic, Pathologic, Environmental Variability Anthony Lang, Toronto |
Permission Not Granted |
13:20 - 13:40 | Challenges to Study Disease Modification in Non-Manifesting at Risk Subjects (gene carriers, “prodromal PD” using new MDS-Criteria) Ron Postuma, Montreal |
Permission Not Granted |
13:40 - 14:00 | Challenges in Neuropathology: Do “copathologies” represent modifiers of PD (Revision) or an invitation to reconsider PD nosology (Reconstruction)? John Trojanowsi, Philadelphia |
Download |
14:00 – 14:20 | The Challenge of Revision vs Reconstruction Alberto Espay, Cincinnati |
Download |
14:20 – 14:50 | Discussion José Obeso, Madrid; Jon Stoessl, Vancouver |
Not Applicable |
14:50 – 15:15 | Refreshment Break | |
EXPERIENCES IN OTHER DISEASES IN NEUROLOGY AND MEDICINE | ||
15:15 – 15:35 | Alzheimer's Disease - problems of retaining old constructs; examples of reasons for and successes in revising concepts of disease subtyping George Perry, San Antonio |
Download |
15:35 – 15:55 | Impact of Breast Cancer Molecular Subtypes on Clinical Decision-Making Philippe Bedard, Toronto |
Download |
15:55 – 16:15 | The Transformation of Cystic Fibrosis: Molecular therapies for a diverse range of genetic causes Steven Rowe, Birmingham |
Download |
16:15 – 16:45 | Discussion Alberto Espay, Cincinnati; Francesca Morgante, London UK |
Not Applicable |
Time | Session Information - Thursday April 25, 2019 | |
---|---|---|
7:00 - 8:00 | Registration and Continental Breakfast | |
Disease Mechanisms | ||
8:00 - 8:30 | Transmission of Misfolded Proteins in Neurodegenerative Disorders: A Common Mechanism of Disease Progression Virginia Lee, Philadelphia |
Download |
8:30 - 8:50 | Mechanistic Insights into GBA1-Associated Parkinson’s Disease and Development of Targeted Therapies Dmitri Krainc, Chicago |
Download |
8:50 - 9:10 | A Genetic Basis for Synaptic-Endosomal Dysfunction in Parkinson’s Disease Matt Farrer, Vancouver |
Download |
9:10 - 9:40 | Discussion Adriano Aguzzi, Zürich; Antonio Strafella, Toronto |
Not |
9:40 - 10:10 | Break | |
10:10 - 10:30 | LRRK2 as a Therapeutic Target for Parkinson’s Disease – Revise or Reconstruct Lorraine Kalia, Toronto |
Download |
10:30 - 10:50 | Bioenergetic Determinants of Neuronal Vulnerability in Parkinson’s Disease James Surmeier, Chicago |
Permission Not Granted |
10:50 - 11:10 | Neuroinflammation and Role of the Microbiome in Parkinson Disease David Standaert, Birmingham |
Download |
11:10 - 12:10 | Discussion Patrik Brundin, Grand Rapids; Andy Singleton, Bethesda |
Not Applicable |
12:10 - 13:10 | Lunch | |
TRANSPLANTATION & OTHER STRATEGIES directed primarily at augmenting dopamine function (Neurorescue/Neurorestoration-based treatments) | ||
13:10 - 13:30 | YES - Nigrostriatal dopamine will remain a primary target and reinnervation should be pursued Roger Barker, Cambridge |
Download |
13:30 - 13:50 | NO - Nigrostriatal dopamine will not remain a primary target and reinnervation should not be pursued. Jeffrey Kordower, Chicago |
Download |
13:50 - 14:30 | Rebuttal and Discussion Andres Lozano, Alfonso Fasano, Toronto |
Permission Not Granted |
14:30 - 15:00 | Break | |
BIG DATA, MACHINE LEARNING, NEW TECHNIQUES, VIRTUAL COHORTS | ||
15:00 - 15:30 | What do PD cohort studies tell us – one disease or many? Caroline Williams-Gray, Cambridge |
Download |
15:30 - 16:00 | Thermodynamically Inspired Biomarkers – Transferring Concepts from Physics and Ecology to Medicine Rudi Balling, Luxembourg |
Permission Not Granted |
16:00 - 16:40 | Discussion Todd Sherer, New York; Ronan Fleming, Leiden |
Not |
Time | Session Information - Friday April 26, 2019 | ||
---|---|---|---|
7:00 - 8:00 | Registration and Continental Breakfast | ||
Trials - Biomarkers, Trial designs, consortiums, etc. What can be pursued in the near future and how? | |||
8:00 - 8:30 | Fit-for-Purpose Applicationsn of Biomarkers in PD Drug Development Jesse Cedarbaum, Boston |
Permission Not Granted |
|
8:30 - 9:00 | Discussion Ken Marek, New Haven |
Not Applicable |
|
Trials - Trial designs including Lessons Learned | |||
9:00 - 9:30 | Lessons from Anti-Amyloid-β Immunotherapies in AD Howard Chertkow, Toronto |
Permission Not Granted |
|
9:30 - 10:00 | Role of Novel End-Points and Evaluations of Response Michael Schwarzschild, Boston |
Permission Not Granted |
|
10:00 - 10:20 | Break | ||
10:20 - 10:50 | Novel trial designs of “disease modifying therapy” in oncology (e.g., I-SPY2) and other diseases Christopher Coffey, Iowa City |
Permission Not Granted |
|
10:50 - 11:20 | Time for a New Framework for ‘Disease Modifying’ Clinical Trials in Parkinson’s Disease Karl Kieburtz, Rochester |
Permission Not Granted |
|
11:20 - 11:50 | Regulatory Modifications that Could Facilitate Development of a Neuroprotective Therapy for PD Warren Olanow, New York |
Permission Not Granted |
|
11:50 - 12:35 | Discussion Hubert Fernandez, Cleveland; Karl Kieburtz, Rochester; Warren Olanow, New York |
Not Applicable |
|
12:35 - 12:50 | Concluding Summary/Remarks Anthony Lang, Toronto |
Date
April 24 – April 26, 2019
Rates
Non-physician Rate (e.g. scientists, fellows, residents) |
$395 |
---|---|
Physician Rate | $495 |
Location
Marriott Downtown at
CF Toronto Eaton Centre
525 Bay Street
Toronto, ON M5G 2L2
More Information
Conference Services
conference@uhn.ca
416-597-3422 ext 3448